Movement Alert｜Boston Scientific Intraday Rise 3.18% in Regular Trading, new product rollout and clinical progress supported sentiment

Market Focus

Nov 10

On November 10, Boston Scientific rose 3.18% in Regular Trading, trading at $44.07 per share, with turnover of $279 million.

The move coincided with recent product and clinical updates, including the launch of the FARAPOINT pulsed field ablation catheter in mainland China and new WATCHMAN-related study results that renewed investor focus on its atrial fibrillation treatment portfolio.

Recent disclosures show FARAPOINT expands the FARAPULSE platform’s linear ablation capabilities, while the platform has treated more than 20,000 patients in mainland China. This followed a separate November 3 announcement that Blackstone Life Sciences and Boston Scientific will co-fund development of the VITALYST heart pump in a $455 million collaboration, marking their first joint funding of a Boston Scientific product. Even so, these positives come after Boston Scientific’s late-October guidance cut tied to the cybersecurity incident, weaker WATCHMAN trends, and Electrophysiology pressure, suggesting the latest rise reflects improving sentiment around pipeline and product-cycle support rather than a full resolution of earnings headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1199302758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199302758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199302758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-10 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199302758","market":"us","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Intraday Rise 3.18% in Regular Trading, new product rollout and clinical progress supported sentiment","media":"Market Focus","content":"<p><p>On November 10, Boston Scientific rose 3.18% in Regular Trading, trading at $44.07 per share, with turnover of $279 million.</p><p>The move coincided with recent product and clinical updates, including the launch of the FARAPOINT pulsed field ablation catheter in mainland China and new WATCHMAN-related study results that renewed investor focus on its atrial fibrillation treatment portfolio.</p><p>Recent disclosures show FARAPOINT expands the FARAPULSE platform’s linear ablation capabilities, while the platform has treated more than 20,000 patients in mainland China. This followed a separate November 3 announcement that Blackstone Life Sciences and Boston Scientific will co-fund development of the VITALYST heart pump in a $455 million collaboration, marking their first joint funding of a Boston Scientific product. Even so, these positives come after Boston Scientific’s late-October guidance cut tied to the cybersecurity incident, weaker WATCHMAN trends, and Electrophysiology pressure, suggesting the latest rise reflects improving sentiment around pipeline and product-cycle support rather than a full resolution of earnings headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Intraday Rise 3.18% in Regular Trading, new product rollout and clinical progress supported sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Intraday Rise 3.18% in Regular Trading, new product rollout and clinical progress supported sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-10 01:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 10, Boston Scientific rose 3.18% in Regular Trading, trading at $44.07 per share, with turnover of $279 million.</p><p>The move coincided with recent product and clinical updates, including the launch of the FARAPOINT pulsed field ablation catheter in mainland China and new WATCHMAN-related study results that renewed investor focus on its atrial fibrillation treatment portfolio.</p><p>Recent disclosures show FARAPOINT expands the FARAPULSE platform’s linear ablation capabilities, while the platform has treated more than 20,000 patients in mainland China. This followed a separate November 3 announcement that Blackstone Life Sciences and Boston Scientific will co-fund development of the VITALYST heart pump in a $455 million collaboration, marking their first joint funding of a Boston Scientific product. Even so, these positives come after Boston Scientific’s late-October guidance cut tied to the cybersecurity incident, weaker WATCHMAN trends, and Electrophysiology pressure, suggesting the latest rise reflects improving sentiment around pipeline and product-cycle support rather than a full resolution of earnings headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1199302758","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199302758","pubTimestamp":1794244537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 10, Boston Scientific rose 3.18% in Regular Trading, trading at $44.07 per share, with turnover of $279 million.The move coincided with recent product and clinical updates, including the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势提醒|波士顿科学日内常规交易上涨3.18%，新产品推出和临床进展支撑情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On November 10, Boston Scientific rose 3.18% in Regular Trading, trading at $44.07 per share, with turnover of $279 million.The move coincided with recent product and clinical updates, including the launch of the FARAPOINT pulsed field ablation catheter in mainland China and new WATCHMAN-related study results that renewed investor focus on its atrial fibrillation treatment portfolio.Recent disclosures show FARAPOINT expands the FARAPULSE platform’s linear ablation capabilities, while the platform has treated more than 20,000 patients in mainland China. This followed a separate November 3 announcement that Blackstone Life Sciences and Boston Scientific will co-fund development of the VITALYST heart pump in a $455 million collaboration, marking their first joint funding of a Boston Scientific product. Even so, these positives come after Boston Scientific’s late-October guidance cut tied to the cybersecurity incident, weaker WATCHMAN trends, and Electrophysiology pressure, suggesting the latest rise reflects improving sentiment around pipeline and product-cycle support rather than a full resolution of earnings headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}